OTC & Consumer Health Intelligence

Radar snapshot

21

Products tracked

4

Fringe signals

4

Segments

Highest velocity signals this month

Phenylephrine — FDA advisory ruling (oral PE ineffective) driving reformulation wave. Pseudoephedrine access now the category bottleneck.

Rx-to-OTC switch pipeline — Opill (norgestrel) established precedent. Migraine and allergy Rx candidates now in active FDA review.

GLP-1 GI adjacency — OTC antinausea and GI comfort products seeing measurable lift from GLP-1 user base.

OTC monograph modernisation — CARES Act administrative rulemaking accelerating. Watch for new ingredient approvals in H2 2026.

Current alerts

RedPhenylephrine (oral) — FDA ruling, reformulation required

RedCharcoal tooth products — ADA / BDA negative evidence statements

AmberOTC monograph modernisation — CARES Act rulemaking ongoing

AmberTopical CBD — FDA regulatory posture still unresolved

SignalRx-to-OTC switch pipeline — migraine and contraceptive candidates active

This edition

21 OTC products and technologies seeded across four therapeutic segments

2 red alerts active — phenylephrine efficacy ruling, charcoal oral care evidence

6 white space opportunities mapped — GLP-1 GI adjacency leads

OTC & Consumer HealthIntelligence